Global Artificial Intelligence in Drug Repurposing Market Revenue Grows at a CAGR of 21.30%

Introduction

Straits Research released its highly anticipated report, “Global Artificial Intelligence in Drug Repurposing Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 1.18 billion in 2025 and is anticipated to grow to USD 6.71 billion by 2034, growing at a CAGR of 21.30% from 2026-2034.

Market Dynamics

The artificial intelligence in drug repurposing market is driven by growing pressure on pharmaceutical and biotechnology companies to optimize research productivity and manage rising development costs by extracting additional value from existing approved and clinical stage drug assets. Artificial intelligence platforms support systematic evaluation of molecular interactions, clinical outcomes, and disease pathways, enabling faster identification of alternative therapeutic indications while reducing early-stage development uncertainty. However, market expansion faces restraint from challenges associated with data quality, heterogeneity, and limited integration across biomedical datasets, which increase model development complexity and slow adoption within fragmented research environments. Despite these limitations, the market presents a strong opportunity through the expansion of collaborative research ecosystems that link artificial intelligence providers, pharmaceutical companies, academic institutions, and healthcare organizations. Access to shared real-world patient data, longitudinal treatment outcomes, and post-marketing evidence supports refined repurposing strategies and indication expansion, positioning artificial intelligence-driven drug repurposing as a central approach for portfolio optimization and lifecycle management across the pharmaceutical industry.

Market Highlights

• Component: Based on the component, the services segment is anticipated to register the fastest growth of 22.12% during the forecast period.
• Technology: Based on technology, the machine learning and deep learning segment dominated the market with a revenue share of 46.78%.
• Application: Based on application, the oncology segment dominated the artificial intelligence in drug repurposing market with a revenue share of 38.98%.
• End Use: Based on end use, the pharmaceutical and biotechnology companies segment held the largest market share of 60.12%.
• Regional Insights: North America held a dominant share of the global market, accounting for 50.14% in 2025.

Competitive Players

1. BenevolentAI
2. BostonGene Corporation
3. Innophore
4. delta4.ai
5. BullFrog AI Holdings, Inc.
6. Owkin, Inc
7. Biovista 
8. Fifty1 Labs
9. BioSpark
10. Others

Recent Developments

August 2025: Fifty1 Labs partnered with BioSpark AI to convert more than 10,000 unstructured clinical case reports into a structured, searchable database comprising over 2,000 real-world patient treatment–outcome pathways, enabling AI-based prioritization of drug repurposing candidates and advancing functional medicine research across chronic fatigue, neuroinflammation, and sleep disorders. 

Segmentation

1. By Component (2026-2034)
   1. Software & Platform
   2. Services
2. By Technology (2026-2034)
   1. Machine Learning/Deep Learning
   2. Natural Language Processing (NLP)
   3. Knowledge Graphs & Network-Based AI
   4. Generative AI & Large Language Models (LLMs)    
   5. Computer Vision
3. By Application (2026-2034)
   1. Oncology    
   2. Neurology
   3. Cardiology
   4. Infectious Diseases
   5. Rare & Orphan Diseases    
   6. Other Therapeutic Areas
4. By End Use (2026-2034)
   1. Pharmaceutical & Biotechnology Companies    
   2. Contract Research Organizations (CROs)
   3. Academic & Research Institutes